US biopharma Biohaven (NYSE: BHVN) and Dutch biotech Merus (Nasdaq: MRUS) have announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs).
The candidates will be developed using Merus’ Biclonics technology platform, and Biohaven’s ADC conjugation and payload platform technologies.
Under the terms of the agreement, Biohaven is responsible for the preclinical ADC generation of three Merus bispecific antibodies under mutually agreed research plans.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze